RealityHackerOpen in RealityHacker ⇢
Science · AI in Drug Discovery · published 2026-11-19T00:00:00+00:00 · via Nature

Corrected Study Identifies METTL1 Inhibition as Potential Cancer Therapy

A corrected study confirms that pharmacological inhibition of the METTL1 enzyme can suppress tumor growth in both solid and blood cancers. The research highlights METTL1’s role in RNA modification and its impact on cancer cell proliferation. The correction addresses an error in reagent reporting, clarifying that NSC-105808, not SML4192, was used in the experiments.

Expanded Detail

A corrected study has reaffirmed that inhibiting the METTL1 enzyme through pharmacological means can suppress tumor growth in both solid and hematologic cancers. The research centers on METTL1’s role in modifying RNA, a process critical to gene expression and cellular function, particularly in cancer cells where such modifications can drive uncontrolled proliferation. The correction specifically addresses a prior error in reagent reporting, clarifying that the compound NSC-105808—not SML4192—was used in the experimental trials. This clarification is essential for reproducibility and scientific integrity, as misidentification of reagents can undermine confidence in results and hinder follow-up studies. The study’s findings, now validated with corrected data, suggest that targeting METTL1 may offer a novel therapeutic strategy across multiple cancer types. While the original study may have been published with inaccuracies, the correction ensures that future research and drug development efforts can build on accurate foundational data.

The correction highlights the importance of rigorous reporting in biomedical research, particularly in high-stakes fields like oncology. Earlier reports may have cited the incorrect reagent, potentially leading other researchers to replicate flawed protocols. The correction process itself reflects the self-correcting nature of science, though it also underscores the risks of premature dissemination of results. The study likely involves researchers from academic or pharmaceutical institutions focused on RNA biology and cancer therapeutics, who may be advancing METTL1 inhibitors toward clinical trials. What remains unclear is the exact mechanism by which METTL1 inhibition affects tumor growth, the specificity of NSC-105808, and whether other compounds targeting METTL1 show similar effects. The path to clinical application remains uncertain, pending further validation and safety testing.

Context

The corrected study on METTL1 inhibition could influence the trajectory of RNA-targeted cancer therapies, a rapidly evolving field where epigenetic and post-transcriptional regulation are gaining prominence. If validated in larger trials, METTL1 inhibitors may become part of a new class of drugs that modulate RNA modifications rather than directly targeting DNA or proteins. This could shift pharmaceutical development toward more nuanced biological targets, potentially reducing side effects. The correction itself may affect trust in preclinical data, particularly in high-impact journals where reagent errors can lead to retractions or retractions of confidence in entire research lines. A comparable case is the 2018 retraction of several high-profile studies on cancer metabolism due to misidentified cell lines, which delayed progress and prompted stricter validation standards. Moving forward, researchers, drug developers, and regulators may place greater emphasis on reagent verification and data transparency. The next steps could include independent replication, development of more specific inhibitors, and early-phase clinical testing—though none are confirmed yet.

Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Read the full article at Nature →
Related stories
Corrected Study Identifies SLAMF6 as a Promising Target to Boost Cancer Immunotherapy · AI in Drug Discovery
Corrected Research Reveals Chromatin Loops Stabilize DNA Replication Forks · Genomics
SARS-CoV-2 mRNA vaccines may enhance cancer immunotherapy response · AI in Drug Discovery
Corrected Study Clarifies Role of Histone Modification in RNA Regulation · Genomics
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Author Correction: Pharmacological inhibition of METTL1 as a therapy against solid and blood cancers.” Browse more stories.